Abstract:Lichen planus is a chronic papulosquamous eruption of the skin, scalp, nails, and mucous membranes. "Pruritic, purple, polygonal, planar, papules, plaques" are the traditional six "P's" of lichen planus. We describe an unusual case of lichen planus presenting as cellulitis. A 64-year-old lady with a past medical history of pyoderma gangrenosum, inclusion body myositis, and chronic kidney disease presented with a two-week history of swelling, erythema, tenderness, hyperkeratotic plaques, and blisters on the medial aspect of both thighs. She had a previous history of pyoderma gangrenosum exacerbations with similar presentations; however, current lesions were different from prior presentations. We considered the differential diagnoses of bacterial cellulitis versus pyoderma gangrenosum exacerbation. Due to the difference in these lesions from previous episodes, the patient was empirically treated for bacterial cellulitis with intravenous cefepime and linezolid. The infectious diseases team was consulted and valacyclovir was added to cover for possible herpes infection, with no improvement in symptomatology. Dermatology was then consulted, and a clinical diagnosis of psoriasiform dermatitis was made. A skin biopsy was obtained and the patient was started on prednisone. There was an immediate improvement in the papules within 24 hours. The papules cleared, leaving behind violaceous flat plaques, clinically diagnosed as lichen planus. The affected area was shrinking as compared to previous examinations. The skin biopsy was reported as chronic psoriasiform dermatitis with the main differential of lichen planus. The patient was discharged home on a tapering dose of oral prednisone, topical clobetasol, and oral moxifloxacin. This case demonstrates the importance of familiarity with rare clinical subtypes as a suspicion for lichen planus. The vesiculobullous subtype of lichen planus, as seen in this patient, tends to present as blisters and cellulitis from infection of the bullae. Treatment of the infection alone is not enough and steroids are essential. This knowledge helps change management, allows for earlier improvement and better patient outcomes.

Oral lichen planus pemphigoides: A case series

A case of systemic lupus erythematosus complicated with pemphigus vulgaris

Lichen Planus Pemphigoides: From Lichenoid Inflammation to Autoantibody-Mediated Blistering

Clinical and immunopathologic findings in oral lichen planus pemphigoides

Lichen planus pemphigoides induced by anti-PD-1 antibody: A case only involved in oral mucosa with excellent topical treatment efficiency

Lichen planus pemphigoides with predominant mucous membrane involvement: a series of 12 patients and a literature review

Oral lichen planus pemphigoid : a case report of a rare disease treated by topical Tacrolimus mouthwash and Hydroxychloroquine

Lichen Planus Pemphigoides Associated with Chinese Herbs

Oral Lichen Planus With Palmoplantar Involvement: A Case Report

Oral Bullous Lichen Planus (BLP) and Oral Lichen Planus Pemphigoides: A Diagnostic Dilemma

An Unusual Presentation of Lichen Planus

Case Report: Mucous Membrane Pemphigoid With IgG and IgA Anti-Laminin γ1 Antibodies and IgA Anti-Laminin α5 Antibodies

Reply: "erosive Oral Lichen Planus As a Sign of Paraneoplastic Pemphigus".

Mucous membrane pemphigoid and lichenoid reactions after immune checkpoint inhibitors: common pathomechanisms

Pembrolizumab-induced lichen planus: A rare immune-related adverse side effect

Paraneoplastic Pemphigus Characterized by Polymorphic Oral Mucosal Manifestations-Report of Two Cases

A Case of an Autoimmune Blistering Disease: Pemphigus Vulgaris

PD-1 Inhibitor Induced Hypertrophic Lichen Planus: A Case Report

Case report: Mucous membrane pemphigoid with complicated autoantibody profile indicating the necessity of comprehensive diagnostic methods and the contribution of IgA autoantibodies

Widespread purplish-red plaques with plasma cell infiltrate: A rare type of lichen planus

Lichen planus-like lesion preceding bullous pemphigoid development after programmed cell death protein-1 inhibitor treatment